Novo Nordisk A/SNVONYSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +30.09% | +19.49% | +12.93% | +5.14% | -8.46% |
| Gross Profit Growth | +30.10% | +17.61% | +10.77% | -4.88% | -12.71% |
| EBITDA Growth | +41.34% | +24.77% | +21.98% | -9.62% | -7.85% |
| Operating Income Growth | +37.25% | +21.81% | +28.98% | -29.98% | -13.92% |
| Net Income Growth | +28.53% | +14.28% | +32.18% | -26.72% | -5.60% |
| EPS Growth | +28.86% | +14.74% | +32.44% | -26.59% | -4.42% |
| EPS Diluted Growth | +28.92% | +14.96% | +32.74% | -26.47% | -4.58% |
| Weighted Average Shares Growth | -0.25% | -0.45% | -0.24% | -0.18% | -0.13% |
| Weighted Average Shares Diluted Growth | -0.38% | -0.54% | -0.42% | -0.31% | -0.28% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +28.79% | +71.80% | -19.24% | +5.15% | -38.06% |
| Free Cash Flow Growth | +0.00% | +88.60% | -34.23% | +2.36% | +0.00% |
| Receivables Growth | +16.15% | +20.37% | +798.71% | +32.92% | -13.40% |
| Inventory Growth | +28.41% | +27.54% | +773.74% | +25.20% | +21.48% |
| Asset Growth | +48.11% | +63.64% | +808.25% | +28.90% | +16.55% |
| Book Value per Share Growth | +34.98% | +40.70% | +941.84% | +41.22% | +35.41% |
| Debt Growth | +280.61% | +340.89% | +1110.53% | +77.66% | +27.41% |
| R&D Expense Growth | +31.95% | +19.78% | -27.69% | +62.24% | +6.13% |
| SG&A Expenses Growth | +8.89% | +11.79% | +17.14% | +4.41% | -14.02% |